We found that TP53-mutated cancer patients with higher expression levels of TP53 have significantly worse OS prognoses than TP53-mutated cancer patients with lower expression levels of TP53 in ACC and UCS, and that the former category also have significantly worse DFS prognoses than the latter category in UCS. Here, TP53 is linked to cancer.